API | rucaparib

rucaparib (rubraca) Report issue

Small molecule Orphan Drug ^FDA Approved ^FDA Accelerated Approval ^FDA Priority Review ^FDA

AACT ChEMBL DrugBank Drugs@FDA MeSH PubChem

Active Ingredient History

NOW

Rucaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of advanced mutant BRCA ovarian cancer. Rucaparib is being investigated in clinical trials against prostate cancer, breast cancer and other neoplasms. ^NCATS

Chemistry

SMILES: CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=CC(F)=CC(N2)=C34
InChIKey: HMABYWSNWIZPAG-UHFFFAOYSA-N
Mol. Mass: 323.3641
ALogP: 2.98 Partition coefficient
ChEMBL Molecules:

rucaparib

rucaparib phosphate

rucaparib camsylate

More Chemistry

Pharmacology

Mechanism of Action:
Multi-specific: Missing data
Black Box: No
Availability: Prescription Only
Delivery Methods: Oral
Pro Drug: No

Drug Pricing (per unit)

United States

$96.0387 - $116.2737

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

ag014699 | ag 014699 | ag-014699 | ag-14447 | ag-14699 | pf-01367338 | rubraca | rucaparib | rucaparib camsylate | rucaparib phosphate

Organizations (62)

Research & Development (61)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (42)

Approved Indications (1)

Ovarian Neoplasms

Experimental Indications - Clinical Trial Phases 1-4 (42)

Adenocarcinoma, Clear Cell (Phase 3)

Biliary Tract Neoplasms (Phase 2)

Biomarkers (Phase 1)

BRCA1 Protein (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 1/Phase 2)

Carcinoma, Endometrioid (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 3)

Carcinoma, Transitional Cell (Phase 2)

Castration (Phase 2)

Colorectal Neoplasms (Phase 1/Phase 2)

Diabetes Mellitus (Phase 2)

Diabetic Retinopathy (Phase 2)

Endometrial Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 1/Phase 2)

Fallopian Tube Neoplasms (Phase 3)

Genital Neoplasms, Female (Phase 1)

Hamartoma (Phase 3)

Head and Neck Neoplasms (Phase 1)

Homologous Recombination (Phase 2)

Leiomyosarcoma (Phase 2)

Loss of Heterozygosity (Phase 2)

Lung Neoplasms (Phase 2)

Melanoma (Phase 2)

Mesothelioma, Malignant (Phase 2)

Mutation (Phase 2)

Neoplasm Metastasis (Phase 1/Phase 2)

Neoplasms ()

Ovarian Neoplasms (Phase 3)

Pancreatic Neoplasms (Phase 2)

Peritoneal Cavity (Phase 3)

Prostatic Neoplasms (Phase 3)

Prostatic Neoplasms, Castration-Resistant (Phase 3)

Small Cell Lung Carcinoma (Phase 2)

Stomach Neoplasms (Phase 1/Phase 2)

Triple Negative Breast Neoplasms (Phase 1/Phase 2)

Ureteral Neoplasms (Phase 2)

Urethral Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Uterine Neoplasms (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 56
# of Trial Organizations: 61

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue